Celldex Therapeutics Inc. (CLDX)
NASDAQ · Healthcare
Celldex Therapeutics Inc. EBITDA 2009–2025
Celldex Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Celldex Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -83.6 M, a 35.09% increase year-over-year.
- Celldex Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -217.0 M, a 225.87% increase year-over-year.
- Celldex Therapeutics Inc. annual ebitda for 2025 was -284.0 M, a 47.99% increase from 2024.
- Celldex Therapeutics Inc. annual ebitda for 2024 was -191.9 M, a 26.64% increase from 2023.
- Celldex Therapeutics Inc. annual ebitda for 2023 was -151.5 M, a 34.89% increase from 2022.
- Celldex Therapeutics Inc. annual ebitda for 2022 was -112.3 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Celldex Therapeutics Inc. EBITDA — FAQ
Celldex Therapeutics Inc. (CLDX) ebitda over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CLDX's ebitda history?
The chart and table above show Celldex Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.